Evidence mapPaperPMID 37467012Full record

ReviewInteractive journal of medical research2023

The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis.

Nor Asiah Muhamad, Nur Hasnah Maamor, Fatin Norhasny Leman, Zuraifah Asrah Mohamad, Sophia Karen Bakon, Mohd Hatta Abdul Mutalip, Izzah Athirah Rosli, Tahir Aris, Nai Ming Lai, Muhammad Radzi Abu Hassan

Open access · goldAbstract readReview
In one paragraph

Review in Interactive journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Nor Asiah Muhamad *Sector for Evidence-based Healthcare, National Institutes of Health, Ministry of Health, Setia Alam, Malaysia.ORCID https://orcid.org/0000-0002-7772-2103
Nur Hasnah Maamor *Sector for Evidence-based Healthcare, National Institutes of Health, Ministry of Health, Setia Alam, Malaysia.ORCID https://orcid.org/0000-0001-6440-1725
Fatin Norhasny LemanSector for Evidence-based Healthcare, National Institutes of Health, Ministry of Health, Setia Alam, Malaysia.ORCID https://orcid.org/0000-0001-7329-8571
Zuraifah Asrah MohamadInstitute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0003-1450-0260
Sophia Karen BakonInstitute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0002-5088-3310
Mohd Hatta Abdul MutalipInstitute for Public Health, National Institutes of Health, Ministry of Health, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0002-2750-5792
Izzah Athirah RosliSector for Evidence-based Healthcare, National Institutes of Health, Ministry of Health, Setia Alam, Malaysia.ORCID https://orcid.org/0000-0002-6501-8565
Tahir ArisInstitute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0002-0205-3080
Nai Ming LaiSchool of Medicine, Taylor's University, Subang Jaya, Selangor, Malaysia.ORCID https://orcid.org/0000-0002-4204-3098
Muhammad Radzi Abu HassanOffice of the Director General of Health, Ministry of Health, Putrajaya, Malaysia.ORCID https://orcid.org/0000-0002-7971-1643
Ministry of Health · MYTaylor's University · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNonalcoholic fatty liver disease (NAFLD) is one of the common causes of chronic liver disease globally. Obesity, metabolic diseases, and exposure to some environmental agents contribute to NAFLD. NAFLD is commonly considered a precursor for some types of cancers. Since the leading causes of death in people with NAFLD are cardiovascular disease and extrahepatic cancers, it is important to understand the mechanisms of the progression of NAFLD to control its progression and identify its association with extrahepatic cancers. Thus, this review aims to estimate the global prevalence of NAFLD in association with the risk of extrahepatic cancers.

objectiveWe aimed to determine the prevalence of various cancers in NAFLD patients and the association between NAFLD and cancer.

methodsWe searched PubMed, ProQuest, Scopus, and Web of Science from database inception to March 2022 to identify eligible studies reporting the prevalence of NAFLD and the risk of incident cancers among adult individuals (aged ≥18 years). Data from selected studies were extracted, and meta-analysis was performed using random effects models to obtain the pooled prevalence with the 95% CI. The quality of the evidence was assessed with the Newcastle-Ottawa Scale.

resultsWe identified 11 studies that met our inclusion criteria, involving 222,523 adults and 3 types of cancer: hepatocellular carcinoma (HCC), breast cancer, and other types of extrahepatic cancer. The overall pooled prevalence of NAFLD and cancer was 26% (95% CI 16%-35%), while 25% of people had NAFLD and HCC (95% CI 7%-42%). NAFLD and breast cancer had the highest prevalence out of the 3 forms of cancer at 30% (95% CI 14%-45%), while the pooled prevalence for NAFLD and other cancers was 21% (95% CI 12%-31%).

conclusionsThe review suggests that people with NAFLD may be at an increased risk of cancer that might not affect not only the liver but also other organs, such as the breast and bile duct. The findings serve as important evidence for policymakers to evaluate and recommend measures to reduce the prevalence of NAFLD through lifestyle and environmental preventive approaches.

trial registrationPROSPERO CRD42022321946; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=321946.

Indexed as

cancercancerscarcinomaextrahepaticfatty liverliverNAFLNAFLDnonalcoholic fatty livernonalcoholic fatty liver diseaseprevalence

Identifiers

PMID37467012
PMCPMC10398554
OpenAlexW4384664987

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.